YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of ...
YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a ...
A large-scale, real-world analysis of 15,639 patients treated with Collagenase SANTYL Ointment underscores the clinical and economic benefits of early enzymatic debridement in wound management. Using ...
Recent research is revealing key insights about the therapeutic potential of clostridial collagenase. Join us for this upcoming webinar to learn about new data on SANTYL® ointment’s unique mechanisms ...
MediWound Ltd. announced the publication of a peer-reviewed post hoc analysis in the journal Wounds, based on data from its Phase II ChronEx clinical trial for patients with venous leg ulcers (VLUs).
FORT WORTH, Texas and PETERBOROUGH, Ontario, Jan. 26 Healthpoint today announced that it will begin marketing Collagenase SANTYL® Ointment to healthcare professionals in Canada. SANTYL® Ointment is a ...
Santyl Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 The Business Research Company's Santyl Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 ...
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are consistent with my ...
Results demonstrate superiority of EscharEx ®, a bromelain-based gel vs. SANTYL ®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback